



# DEA Reporting Requirements, Reporting Tools, & Drug Trends

E. Ryan Dorsey



April 1 - 3, 2025

Orlando, Florida



**The contents of this document do not have the force and effect of law and are not meant to bind the public or DEA in any way.**

**This document is intended only to provide clarity to the public regarding existing requirements under the law or agency policies.**

**I have no financial relationship to disclose.**





**This presentation is for educational purposes.**

**Materials, images, or sounds authored or created by parties other than DEA may be subject to copyright and are used herein in accordance with the fair use provision of Title 17 United States Code Section 107. DEA's use of these materials does not authorize persons outside of DEA further distribute or use copyrighted materials.**



# Diversion Data Sources



## ➤ Automation of Reports & Consolidated Orders System (ARCOS)

- An automated, comprehensive drug reporting system that monitors the flow of controlled substances from point of manufacture to point of sale or distribution. ARCOS tracks transactions for all schedules I and II, schedule III narcotics, GHB and select schedule III and IV psychotropic drugs (manufacturers only).

## ➤ Theft/Loss Reporting System (TLR )

- Contains data generated from DEA Forms 106 and 107. Federal regulations require registrants to notify DEA field offices of thefts or losses of any controlled substance or listed chemicals.

## ➤ Suspicious Orders Reporting System (SORS)

- DEA registrants that distribute controlled substances to other DEA registrants are required to report any suspicious orders to DEAs SORS centralized data system. Suspicious orders may include, but are not limited to: an order of controlled substance of unusual size; an order of deviating substantially from a normal pattern or orders of unusual frequency.






# **Automation of Reports and Consolidated Orders System**

## **(ARCOS)**




# Sales of Opioids & Stimulants to Retail Registrants Nationwide

## January 2020 – December 2024




# Sales of Hydrocodone & Oxycodone to Retail Registrants Nationwide January 2020 – December 2024



Source: ARCOS  
Date Prepared: 03/14/2025

# Sales of Amphetamine & Methylphenidate to Retail Registrants Nationwide

## January 2020 – December 2024



Source: ARCOS  
Date Prepared: 03/14/2025



# Sales of Opioids to Retail Registrants by Drug


## January 2020 – December 2024



DRUG NAME	2020	2021	2022	2023	2024	TOTAL DOSAGE UNITS
HYDROCODONE	3,745,155,114	3,549,667,547	3,338,112,322	3,124,649,931	3,001,595,695	16,759,180,609
OXYCODONE	3,349,531,426	3,250,986,343	3,144,469,671	3,099,303,164	3,115,822,207	15,960,112,811
BUPRENORPHINE	696,556,703	728,200,599	761,517,682	803,574,841	855,810,386	3,845,660,211
MORPHINE	425,400,151	387,864,479	359,559,815	339,110,969	321,594,267	1,833,529,681
CODEINE	409,113,182	367,439,727	325,103,585	300,306,330	275,434,561	1,677,397,385
METHADONE	245,414,520	220,839,943	201,788,061	186,808,491	177,237,058	1,032,088,073
HYDROMORPHONE	181,971,641	173,700,059	167,809,669	163,472,642	141,803,555	828,757,566
TAPENTADOL	37,619,555	32,286,002	28,809,811	23,748,828	20,634,475	143,098,671
FENTANYL BASE	30,067,197	25,987,185	22,812,425	19,663,021	18,367,948	116,897,776
OXYMORPHONE	19,426,188	15,284,758	11,785,641	6,291,051	4,253,969	57,041,607
LEVORPHANOL	2,658,600	1,910,700	1,291,000	1,095,300	1,165,600	8,121,200
DIHYDROCODEINE	1,828,703	1,327,792	655,532	382,880	100	4,195,007
OPIUM (Belladonna Supp.)	582,776	604,432	300,894	4	26,688	1,514,794
MEPERIDINE	127,030	210,397	210,568	179,819	169,350	897,164
NOROXYMORPHONE	56,718	14,426	0	0	0	71,144
SUFENTANIL BASE	6,542	13,990	21,350	16,770	9,480	68,132
THEBAINE	30,990	6,930	0	0	0	37,920

Hydrocodone  
16.7 Billion Dosage Units


Oxycodone  
15.9 Billion Dosage Units



Remaining ARCOS Reportable Drugs  
9.5 Billion Dosage Units


# Sales of Stimulants to Retail Registrants by Drug

## January 2020 – December 2024



DRUG NAME	2020	2021	2022	2023	2024	TOTAL DOSAGE UNITS
AMPHETAMINE	1,987,198,390	2,133,246,004	2,272,061,571	2,234,345,200	2,512,614,883	11,139,466,048
METHYLPHENIDATE	865,207,819	889,652,175	952,279,360	1,005,384,866	1,060,055,104	4,772,579,324
LISDEXAMFETAMINE	380,841,676	391,618,298	423,471,846	520,423,401	528,190,743	2,244,545,964
METHAMPHETAMINE	1,386,400	1,296,600	970,300	64,300	258,600	3,976,200


# Per Capita Opioid Sales Nationwide January - December 2024



Source: ARCOS  
Date Prepared: 03/14/2025

# Per Capita Stimulant Sales Nationwide

## January - December 2024





# **THEFT LOSS REPORTING (TLR)**



# Theft Loss Reporting (TLR)



## Theft/Loss Types

- LOSSES IN TRANSIT
- PACKAGING DISCREPANCY
- EMPLOYEE THEFT (OR SUSPECTED)
- CUSTOMER THEFT (OR NON-EMPLOYEE)
- BREAK-IN/BURGLARY
- ROBBERY
- DISASTER (FIRE, WEATHER, ETC.)
- HIJACKING OF TRANSPORT VEHICLE

## Business Activities

- PHARMACY
- HOSPITAL
- PRACTITIONER
- MID LEVEL PRACTITIONER
- TEACHING INSTITUTION
- NARCOTIC TREATMENT PROGRAM
- ANALYTICAL LAB
- CANINE HANDLER
- REVERSE DISTRIBUTOR
- DISTRIBUTOR
- MANUFACTURER
- IMPORTER
- EXPORTER



# Active Pharmacies w/Reported Thefts (all types) Nationwide 2023 – 2024




\*schedules II and III narcotics

RANK	STATE	ACTIVE* PHARMACIES	PHARMACIES W/REPORTED THEFTS	PERCENTAGE
1	DE	201	65	32%
2	WA	1,245	318	26%
3	NH	258	65	25%
4	CO	829	206	25%
5	CT	683	166	24%
6	CA	6,146	1,444	23%
7	VA	1,528	358	23%
8	OR	646	148	23%
9	NV	487	111	23%
10	AZ	1,169	253	22%
11	IN	1,148	246	21%
12	PA	2,831	583	21%
13	SC	1,073	220	21%
14	MD	1,201	234	19%
15	DC	145	28	19%
16	AL	1,301	246	19%
17	ID	350	66	19%
18	RI	170	31	18%
19	TN	1,501	273	18%
20	NC	2,034	352	17%
21	HI	211	36	17%
22	MI	2,424	406	17%
23	UT	522	87	17%
24	OH	2,280	376	16%
25	GA	2,213	355	16%
26	FL	4,798	769	16%
27	NJ	2,117	332	16%

RANK	STATE	ACTIVE* PHARMACIES	PHARMACIES W/REPORTED THEFTS	PERCENTAGE
28	ME	291	45	15%
29	MN	956	144	15%
30	AK	100	15	15%
31	NM	325	45	14%
32	MT	247	34	14%
33	KY	1,152	156	14%
34	SD	191	25	13%
35	IL	2,101	266	13%
36	MS	699	88	13%
37	WY	120	15	13%
38	MA	1,111	135	12%
39	MO	1,284	155	12%
40	IA	698	83	12%
41	WV	532	63	12%
42	AR	773	90	12%
43	WI	1,073	119	11%
44	TX	5,418	583	11%
45	KS	632	66	10%
46	OK	904	85	9%
47	NY	4,944	460	9%
48	LA	1,227	113	9%
49	NE	442	40	9%
50	VT	140	10	7%
51	ND	178	10	6%
52	PR	1,090	32	3%
GRAND TOTAL		66,139	10,651	16%

# Active\* Pharmacies w/Reported Thefts (all types) Nationwide 2023 – 2024

\*schedules II and III narcotics



U.S. Average: 16% of Pharmacies w/Reported Thefts


- Above Average = 20% of Pharmacies or more
- Average = 13% – 19% of Pharmacies
- Below Average = 12% of Pharmacies



# Reported Pharmacy Break-Ins & Robberies Nationwide


## Number of Thefts/Losses

### 2023 - 2024




# Reported Thefts/Losses of Promethazine w/Codeine Nationwide 2023 – 2024

## All Business Activities – All Theft Types




# Reported Thefts/Losses of Ketamine Nationwide 2023 – 2024

## All Business Activities – All Theft Types



# Reported Thefts/Losses by Business Activity Nationwide 2023 - 2024

## All Drugs – All Theft Types



REMAINING BUSINESS ACTIVITIES	NUMBER OF THEFTS
DISTRIBUTORS (1.4 million Opioids 236k Stimulants)	2,098
PRACTITIONERS	1,288
MID LEVEL PRACTITIONERS	181
NARCOTIC TREATMENT PROGRAM	159
MANUFACTURERS (1.1 million Opioids/119k Stimulants)	126
RESEARCHERS	29
CANINE HANDLERS	17
ANALYTICAL LABS	12
TEACHING INSTITUTIONS	7
IMPORTERS	1
EXPORTERS	1


# Reported Thefts/Losses by Business Activity

## 2023 - 2024

### All Theft Types – All Drugs




BUSINESS ACTIVITY	THEFT/LOSS TYPE	2023	2024	% CHANGE	NUMBER OF THEFTS
PHARMACY	LOSS IN TRANSIT	8,645	9,219	7%	17,864
	PACKAGING DISCREPANCY	4,760	4,451	-6%	9,211
	EMPLOYEE THEFT (OR SUSPECTED)	3,303	3,445	4%	6,748
	OTHER THEFT TYPES	1,416	1,517	7%	2,933
TOTAL		18,124	18,632	3%	36,756
REVERSE DISTRIBUTOR	PACKAGING DISCREPANCY	4,269	5,077	19%	9,346
	CUSTOMER THEFT (OR NON-EMPLOYEE)	3,526	4,613	31%	8,139
	EMPLOYEE THEFT (OR SUSPECTED)	400	432	8%	832
	OTHER THEFT TYPES	29	38	31%	67
TOTAL		8,224	10,160	24%	18,384
HOSPITAL	EMPLOYEE THEFT (OR SUSPECTED)	2,011	1,876	-7%	3,887
	LOSS IN TRANSIT	986	1,088	10%	2,074
	PACKAGING DISCREPANCY	330	324	-2%	654
	OTHER THEFT TYPES	81	111	37%	192
TOTAL		3,408	3,399	-0.3%	6,807
DISTRIBUTOR	LOSS IN TRANSIT	763	798	5%	1,561
	PACKAGING DISCREPANCY	212	187	-12%	399
	HIJACKING OF TRANSPORT VEHICLE	29	12	-59%	41
	OTHER THEFT TYPES	45	52	16%	97
TOTAL		1,049	1,049	0.0%	2,098
PRACTITIONER	EMPLOYEE THEFT (OR SUSPECTED)	346	345	0%	691
	PACKAGING DISCREPANCY	137	126	-8%	263
	LOSS IN TRANSIT	52	51	-2%	103
	OTHER THEFT TYPES	108	123	14%	231
TOTAL		643	645	0.3%	1,288



# 2023 – 2024 Top Drugs Reported as a Theft/Loss All Theft Types



DRUG NAME	2023	2024	% Change
OXYCODONE	2,134,622	2,803,809	31%
HYDROCODONE	1,502,021	2,287,810	52%
ALPRAZOLAM	1,167,304	1,140,087	-2%
AMPHETAMINE	808,204	962,264	19%
METHYLPHENIDATE	432,983	524,164	21%
TRAMADOL	445,461	493,060	11%



Source: TLR  
Date Prepared: 03/14/2025



# **SUSPICIOUS ORDERS REPORTING**


## **(SORS)**



# Top 10 Reported SORS in 2024 - by Drug



DRUG	2023	2024	% Change
OXYCODONE	116,982	120,580	3%
AMPHETAMINE	104,597	86,342	-17%
METHYLPHENIDATE	70,616	75,512	7%
TRAMADOL	54,340	61,734	14%
HYDROCODONE	66,208	55,582	-16%
BUPRENORPHINE	65,811	55,570	-16%
ALPRAZOLAM	83,568	53,856	-36%
LISDEXAMFETAMINE	54,860	45,209	-18%
MORPHINE	39,085	41,096	5%
HYDROMORPHONE	21,170	27,599	30%






# Reported SORS Nationwide/Number of Reporters

## All Controlled Substances


January 1, 2020 – December 31, 2024



Reported SORS Nationwide/Number of Reporters

OPIOIDS

January 1, 2020 – December 31, 2024




	SORS	Reporters
2020, Q1	31,747	108
2020, Q2	39,638	105
2020, Q3	47,545	105
2020, Q4	46,725	110
2021, Q1	38,793	106
2021, Q2	43,592	105
2021, Q3	46,444	107
2021, Q4	44,355	119
2022, Q1	44,637	116
2022, Q2	45,891	106
2022, Q3	66,285	118
2022, Q4	78,048	123
2023, Q1	76,695	126
2023, Q2	111,539	133
2023, Q3	112,336	127
2023, Q4	113,835	122
2024, Q1	102,308	130
2024, Q2	97,787	119
2024, Q3	99,160	119
2024, Q4	109,298	125

# Reported SORS Nationwide/Number of Reporters

## STIMULANTS

January 1, 2020 – December 31, 2024




	SORS	Reporters
2020, Q1	11,151	80
2020, Q2	8,947	70
2020, Q3	12,054	71
2020, Q4	14,666	72
2021, Q1	13,842	72
2021, Q2	17,852	69
2021, Q3	19,107	71
2021, Q4	26,423	75
2022, Q1	23,802	65
2022, Q2	29,087	70
2022, Q3	39,541	80
2022, Q4	67,847	87
2023, Q1	59,108	87
2023, Q2	63,595	90
2023, Q3	55,400	87
2023, Q4	51,984	88
2024, Q1	45,063	88
2024, Q2	47,211	89
2024, Q3	34,231	89
2024, Q4	80,544	96

# Suspicious Orders Reported on Non-ARCOS Drugs 2020 – 2024




YEAR	TOTAL SORS	NON-ARCOS	% REPORTED SORS
2020	380,968	146,716	39%
2021	614,141	163,565	27%
2022	753,844	206,714	27%
2023	1,015,969	358,558	35%
2024	840,230	272,311	32%



# Suspicious Orders Reported on Non-Controlled Drugs 2020 – 2024



YEAR	TOTAL SORS	NON-CONTROLLED	% REPORTED SORS
2020	380,968	42,425	11%
2021	614,141	221,295	36%
2022	753,844	179,622	24%
2023	1,015,969	73,483	7%
2024	840,230	18,787	2%




NUMBER OF SORS REPORTED BY  
SUPPLY CHAIN CONFERENCE ATTENDEES  
(Pharmacies, Manufacturers, & Distributors)

		Oct 1, 2023 May 2,2024			May 3, 2024December 31, 2024			Percentage Increase of SORS Reporting Post Conference
Registrant Type	Number of Attendees	Number of Attendees Reporting SORS	Percentage of Attendees Reporting SORS	Number of SORS Reported	Number of Attendees Reporting SORS	Percentage of Attendees Reporting SORS	Number of SORS Reported	
Pharmacies	77	0	0%	0	0	0%	0	0%
Manufacturers	144	5	3%	8,631	7	5%	15,714	82%
Distributors	125	48	38%	103,476	42	34%	106,178	2%

# SORS REPORTED

## PRE – POST SUPPLY CHAIN CONFERENCE





## REPORTED SORS BY BUSINESS TYPE

### U.S. TOTAL

TOTAL ARCOS ACTIVE <b>DISTRIBUTORS</b> WITH ACTIVITY IN 2024	398
TOTAL ARCOS ACTIVE <b>DISTRIBUTORS</b> WITH SORS ACTIVITY REPORTED IN 2024	159
REGISTRANTS WITH ACTIVITY & NO REPORTED SORS	239
<b>% OF REGISTRANTS WITH ACTIVITY &amp; NO REPORTED SORS</b>	60%

### U.S. TOTAL

TOTAL AROCS ACTIVE <b>MANUFACTURERS</b> WITH ACTIVITY IN 2024	301
TOTAL ARCOS ACTIVE <b>MANUFACTURERS</b> WITH SORS ACTIVITY REPORTED IN 2024	10
REGISTRANTS WITH ACTIVITY & NO REPORTED SORS	291
<b>% OF REGISTRANTS WITH ACTIVITY &amp; NO REPORTED SORS</b>	97%





# PDMP: Trends Analysis



April 1 - 3, 2025


Orlando, Florida

# Opioid Prescribing

## Data Analytics 2023 – 2025



**Findings:** Change in recent dispensing patterns for Oxycodone and Hydrocodone. Payment types used for early refills of Opioids differ from overall behavior.



Opioid Payment Types Breakdown			
Payment Type	Early Refill	Overall	Average Age of R Patient
COMMERCIAL INSURANCE	50.65%	54.80%	56.42
CASH/PRIVATE PAY	31.08%	16.21%	50.49
MEDICAID	3.63%	6.74%	49.66
MEDICARE	11.35%	19.94%	65.47
TRICARE	0.20%	0.08%	59.92
WORKERS' COMP	0.88%	0.92%	56.79

Note: Early refills include instances when a patient fills the same drug name and strength 8 or more days early according to the end date of a prior prescription (dispense date + supply in days).

# Opioid Prescribing (Cont'd)


## Data Analytics 2023 – 2025



**Findings:** Specific controlled substances are commonly filled by patients with existing drug charges.



**% of Opioid Prescriptions Filled by Drug Charge Patients (CLEAR)**




Note: Patients analyzed are run through a CLEAR Criminal & Arrest Records search to identify those with drug charges by matching on first name, last name, date of birth, and state.

# Stimulant Prescribing

## Data Analytics 2023 – 2025



**Findings:** Patients in recent years will travel further to a pharmacy to fill Stimulants early. Out-of-pocket payments are more common when Stimulants are filled early.



Stimulant RX Payment TypeEarly Refills vs. Overall		
Payment Type	Early Refill	Overall
COMMERCIAL INSURANCE	65.37%	74.37%
CASH/PRIVATE PAY	23.31%	10.54%
INDIAN NATION	0.00%	0.00%
MEDICAID	7.09%	10.52%
MEDICARE	3.10%	3.57%
TRICARE	0.01%	0.01%
WORKERS' COMP	0.06%	0.05%
UNKNOWN	1.06%	0.94%

Note: Early refills include instances when a patient fills the same drug name and strength 8 or more days early according to the end date of a prior prescription (dispense date + supply in days).

# Stimulant Prescribing (Cont'd)


Data Analytics 2023 – 2025



**Findings:** Prescribing of higher strength stimulants has increased.



% of Total Patients with Top 4 Amphetamine Strengths by Year




# Drug Combinations

Data Analytics 2023 – 2025




**Findings:** Stimulant-based drug-combinations are increasing YoY while Opioid-based combinations wane. Opioid-based combinations remain the most prevalent combinations analyzed.

% of Total Drug Combo Rx's by Year



Top Drug Combos Based on Prevalence



Note: Drug combinations include any period of overlap when a single patient had all components of a combination in their possession.

# Drug Combinations (Cont'd)


Data Analytics 2023 – 2025




**Findings:** Patients are more likely to doctor shop for Opioid-based combinations and this likelihood increases when seeking combinations involving both Opioids and Stimulants. Patients are willing to see prescribers farther away to fill Stimulant-based combinations in recent years.



% of Drug Combo Patients Using Multiple Prescribers



Avg Patient-to-Prescriber Distance for Drug Combo Prescriptions



Note: Drug combinations include any period of overlap a single patient had all components of a combination in possession.




# Distance

Analytics Support 2023 – 2025



**Findings:** Distances traveled by patients to prescribers and pharmacies can be affected by payment type.





# Distance (Cont'd)

Analytics Support 2023 – 2025



**Findings:** Average distances that patients travel differs between Opioids and Stimulants. Patients are more likely to see out of state practitioners for Stimulants than for Opioids.

Average Entity Distance by Category				
		Year		
		2023	2024	2025
Opioid	Average Pharmacy Distance	25.16	27.64	16.53
	Average Prescriber Distance	29.43	28.13	18.96
Stimulant	Average Pharmacy Distance	27.19	23.13	14.38
	Average Prescriber Distance	38.76	35.05	40.59

Out Of State Entity Matrix (In Percentages)					
Investigation Year	Drug Category	Out of State Pharmacy In State Prescriber	Out of State Prescriber In State Pharmacy	Out of State Pharmacy Out of State Prescriber	In State Prescriber In State Pharmacy
2023	OPIOID	0.75	0.57	0.78	96.12
2023	STIMULANT	0.56	3.53	1.35	78.88
2024	OPIOID	0.79	0.96	0.95	94.52
2024	STIMULANT	0.65	3.13	1.88	89.56